CY1123615T1 - Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5 - Google Patents

Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5

Info

Publication number
CY1123615T1
CY1123615T1 CY20201101085T CY201101085T CY1123615T1 CY 1123615 T1 CY1123615 T1 CY 1123615T1 CY 20201101085 T CY20201101085 T CY 20201101085T CY 201101085 T CY201101085 T CY 201101085T CY 1123615 T1 CY1123615 T1 CY 1123615T1
Authority
CY
Cyprus
Prior art keywords
bind
polystena
multispecies
fusion proteins
disclosure relates
Prior art date
Application number
CY20201101085T
Other languages
English (en)
Inventor
John C. TIMMER
Kyle S. JONES
Amir S. RAZAI
Abrahim HUSSAIN
Katelyn M. WILLIS
Quinn Deveraux
Brendan P. ECKELMAN
Original Assignee
Inhibrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx, Inc. filed Critical Inhibrx, Inc.
Publication of CY1123615T1 publication Critical patent/CY1123615T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η αποκάλυψη αφορά σε γενικές γραμμές μόρια που συνδέονται ειδικά με τον υποδοχέα θανάτου 5 (DR5), ένα μέλος της υπεροικογένειας υποδοχέων TNF (TNFRSF). Ειδικότερα η αποκάλυψη αφορά πολυσθενή και πολυειδικά μόρια που δεσμεύουν τουλάχιστον τον DR5.
CY20201101085T 2015-07-16 2020-11-16 Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5 CY1123615T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Publications (1)

Publication Number Publication Date
CY1123615T1 true CY1123615T1 (el) 2022-03-24

Family

ID=57757772

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101085T CY1123615T1 (el) 2015-07-16 2020-11-16 Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5

Country Status (25)

Country Link
US (3) US10308720B2 (el)
EP (2) EP3798232A1 (el)
JP (3) JP6807606B2 (el)
KR (1) KR20180030518A (el)
CN (2) CN114106178A (el)
AU (2) AU2016291701B2 (el)
BR (1) BR112018000584A2 (el)
CA (1) CA2991634A1 (el)
CY (1) CY1123615T1 (el)
DK (1) DK3322734T3 (el)
ES (1) ES2833773T3 (el)
HK (1) HK1254433A1 (el)
HR (1) HRP20201785T1 (el)
HU (1) HUE051896T2 (el)
IL (3) IL307994A (el)
LT (1) LT3322734T (el)
MX (2) MX2018000523A (el)
PL (1) PL3322734T3 (el)
PT (1) PT3322734T (el)
RS (1) RS61062B1 (el)
RU (2) RU2748620C2 (el)
SG (1) SG10201912410TA (el)
SI (1) SI3322734T1 (el)
WO (1) WO2017011837A2 (el)
ZA (1) ZA201800238B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018250641A1 (en) 2017-04-11 2019-10-31 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
CA3086653A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universitat Wurzburg Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa)
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
TW202245839A (zh) * 2021-02-19 2022-12-01 美商英伊布里克斯公司 Dr5結合多肽之調配物
WO2023196943A1 (en) * 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
TW202410919A (zh) * 2022-05-23 2024-03-16 美商英伊布里克斯公司 Dr5促效劑與iap拮抗劑之組合療法
WO2024069180A2 (en) 2022-09-28 2024-04-04 LiliumX Ltd. Multivalent proteins and screening methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3298879B2 (ja) 1990-12-20 2002-07-08 イグジス，インコーポレイテッド 結合タンパク質の最適化
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
CN101160524A (zh) 2005-02-24 2008-04-09 西米尼斯公司 用于生物样品分类的组合物和方法
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
TW200804425A (en) 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
WO2009073631A2 (en) 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US20110166076A1 (en) 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2010107778A1 (en) 2009-03-18 2010-09-23 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
WO2010115141A2 (en) 2009-04-02 2010-10-07 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2563816B1 (en) 2010-04-27 2014-11-12 National Research Council of Canada Anti-icam-1 single domain antibody and uses thereof
ES2617446T3 (es) * 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
EP2632949B1 (en) 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
EP2655402A1 (en) 2010-12-23 2013-10-30 Intercell Austria AG Oprf/i agents and their use in hospitalized and other patients
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
BR112014009069A2 (pt) * 2011-10-13 2020-10-27 Bristol-Myers Squibb Company polipeptídeos de anticorpo que antagonizam cd40l
JP2014533249A (ja) 2011-11-07 2014-12-11 メディミューン，エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
WO2013091103A1 (en) 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
MX2014010495A (es) 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20140161796A1 (en) 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
EP2917236A2 (en) 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US9862777B2 (en) 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
KR20160103007A (ko) * 2014-01-10 2016-08-31 각코호진 데이쿄 헤이세이 다이가쿠 재조합 편성 혐기성 그램 양성균

Also Published As

Publication number Publication date
AU2016291701A1 (en) 2018-01-25
SI3322734T1 (sl) 2021-02-26
US11976126B2 (en) 2024-05-07
SG10201912410TA (en) 2020-02-27
ES2833773T3 (es) 2021-06-15
PT3322734T (pt) 2020-11-30
IL256772A (en) 2018-03-29
CN114106178A (zh) 2022-03-01
IL256772B (en) 2022-05-01
EP3798232A1 (en) 2021-03-31
EP3322734A2 (en) 2018-05-23
US11117973B2 (en) 2021-09-14
RS61062B1 (sr) 2020-12-31
RU2021111382A (ru) 2021-05-21
MX2018000523A (es) 2018-04-13
CA2991634A1 (en) 2017-01-19
MX2023002379A (es) 2023-03-21
JP7244938B2 (ja) 2023-03-23
HK1254433A1 (zh) 2019-07-19
LT3322734T (lt) 2021-02-10
US20220064318A1 (en) 2022-03-03
US20190309083A1 (en) 2019-10-10
JP6807606B2 (ja) 2021-01-06
WO2017011837A2 (en) 2017-01-19
AU2016291701B2 (en) 2022-09-29
PL3322734T3 (pl) 2021-05-04
KR20180030518A (ko) 2018-03-23
BR112018000584A2 (pt) 2018-09-11
HUE051896T2 (hu) 2021-03-29
WO2017011837A3 (en) 2017-03-02
US20170015753A1 (en) 2017-01-19
RU2018102803A (ru) 2019-08-19
DK3322734T3 (da) 2020-10-26
JP2018522888A (ja) 2018-08-16
CN107922491A (zh) 2018-04-17
HRP20201785T1 (hr) 2021-01-22
RU2018102803A3 (el) 2019-12-27
US10308720B2 (en) 2019-06-04
RU2748620C2 (ru) 2021-05-28
JP2021046414A (ja) 2021-03-25
EP3322734B1 (en) 2020-09-09
IL292037A (en) 2022-06-01
CN107922491B (zh) 2021-09-28
JP2023022214A (ja) 2023-02-14
EP3322734A4 (en) 2019-04-17
IL307994A (en) 2023-12-01
AU2022291498A1 (en) 2023-02-02
ZA201800238B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
CY1123615T1 (el) Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MX2024007711A (es) Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
MX2024004017A (es) Proteinas de fusion de union a ox40 multivalentes y multiespecificas.
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
EA202092435A2 (ru) Моноклональные антитела против bcma
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2016000293A1 (es) Diacuerpos fc monovalentes biespecíficos que son capaces de unirse a cd32b y cd79b y usos de los mismos
BR112016022841A2 (pt) cadeia j modificada
BR112016018313A2 (pt) moléculas de ligação multiespecíficas iga
DK3200822T3 (da) Bindingsmolekyler, i særdeleshed antistoffer, der binder til l1cam (cd171)
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
DK3144676T3 (da) Kit omfattende antistof der specifikt binder til komplementfaktor b protein og antistof der specifikt binder til kulhydratantigen 19-9 protein til diagnosticering af cancer i bugspytkirtlen